Vertex Pharmaceuticals chief Reshma Kewalramani said AI could reduce the time spent on drug-approval paperwork from months to ...
In the U.S., revenue climbed 15%, to $1.98 billion, helped by strong demand and higher pricing for its cystic-fibrosis drugs, the company said. Its Casgevy and Journavx drugs, which treat severe ...
Zacks Investment Research on MSN
Vertex Gears Up to Report Q3 Earnings: Is a Beat in the Cards?
We expect Vertex Pharmaceuticals VRTX to surpass expectations when it reports its third-quarter 2025 results on Nov. 3, after ...
Advocacy groups form a buyer’s club to obtain generic versions of pricey Vertex cystic fibrosis drug
Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...
KING OF PRUSSIA, Pa., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ: VERX) (“Vertex” or the “Company”), a leading global provider of indirect tax solutions, today announced financial results ...
Jennifer Simonson is a business journalist with a decade of experience covering entrepreneurship and small business. Drawing on her background as a founder of multiple startups, she writes for Forbes ...
iShares Biotechnology ETF (IBB) offers targeted exposure to the U.S. biotechnology sector, providing investors with access to a broad basket of industry-leading biotech equities. The fund's strategy ...
Apacer (TWSE: 8271), a global leader in industrial memory and storage solutions, will showcase its latest innovations at embeddedworld North America 2025. Visitors will explore Apacer's advancements ...
Kickstart your day with a smooth boost from the Sunrise Spark gummies. This combination of Yerba Mate, a naturally ...
Life Sciences Investors offers a 10.1% yield, diversified healthcare exposure, and trades at a NAV discount. Learn why HQL ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback